Working… Menu

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04259255
Recruitment Status : Recruiting
First Posted : February 6, 2020
Last Update Posted : March 18, 2021
Massachusetts General Hospital
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma America Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022